Loading
Latest filing published 22 Mar 2022 for Adamis Pharmaceuticals Corp, €4,459.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Ronald B. Moss in Adamis Pharmaceuticals Corp, where the filings describe the role as senior executive. Between 30 January 2019 and 18 March 2022, the trades on record add up to 14 filings.
Sales make up the whole of the open-market record (11 sales, €88k). Besides market trades, the filings include 1 share grant and 2 option exercises. In 2022 alone, the filings show no purchases and 1 sale.
The record was last updated on 22 March 2022 with an open-market sale (€4,459) in Adamis Pharmaceuticals Corp. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations